H
Harro Seelaar
Researcher at Erasmus University Rotterdam
Publications - 112
Citations - 11447
Harro Seelaar is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Frontotemporal dementia & Medicine. The author has an hindex of 25, co-authored 63 publications receiving 9260 citations. Previous affiliations of Harro Seelaar include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Simon Ducharme,Annemiek Dols,Robert Laforce,Emma Devenney,Fiona Kumfor,Jan Van den Stock,Caroline Dallaire-Théroux,Harro Seelaar,Flora Gossink,Everard G. B. Vijverberg,Edward D. Huey,Mathieu Vandenbulcke,Mario Masellis,Calvin Trieu,Chiadi U. Onyike,Paulo Caramelli,Leonardo Cruz de Souza,Alexander Santillo,Maria Landqvist Waldö,Ramon Landin-Romero,Olivier Piguet,Wendy Kelso,Dhamidhu Eratne,Dennis Velakoulis,Manabu Ikeda,David C. Perry,Peter Pressman,Bradley F. Boeve,Rik Vandenberghe,Mario F. Mendez,Carole Azuar,Richard Levy,Isabelle Le Ber,Sandra Baez,Alan J. Lerner,Ratnavalli Ellajosyula,Florence Pasquier,Daniela Galimberti,Elio Scarpini,John C. van Swieten,Michael Hornberger,Howard J. Rosen,John R. Hodges,Janine Diehl-Schmid,Yolande A.L. Pijnenburg +44 more
TL;DR: The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment and clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of b vFTD.
Journal ArticleDOI
Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia
David Bergeron,David Bergeron,Maria Luisa Gorno-Tempini,Gil D. Rabinovici,Miguel A. Santos-Santos,William W. Seeley,Bruce L. Miller,Yolande A.L. Pijnenburg,M. Antoinette Keulen,Colin Groot,Bart N.M. van Berckel,Wiesje M. van der Flier,Philip Scheltens,Jonathan D. Rohrer,Jason D. Warren,Jonathan M. Schott,Nick C. Fox,Raquel Sánchez-Valle,Oriol Grau-Rivera,Ellen Gelpi,Harro Seelaar,Janne M. Papma,John C. van Swieten,John R. Hodges,John R. Hodges,John R. Hodges,Cristian E. Leyton,Olivier Piguet,Olivier Piguet,Olivier Piguet,Emily Rogalski,Emily Rogalski,M.-Marsel Mesulam,Lejla Koric,Kristensen Nora,Jeéreémie Pariente,Bradford C. Dickerson,Ian R. A. Mackenzie,Ging-Yuek Robin Hsiung,Serge Belliard,David J. Irwin,David A. Wolk,Murray Grossman,Matthew Jones,Jennifer M. Harris,David G. Mann,Julie S. Snowden,Patricio Chrem-Méndez,Ismael Calandri,Alejandra A. Amengual,Carole Miguet-Alfonsi,Eloi Magnin,Giuseppe Magnani,Roberto Santangelo,Vincent Deramecourt,Florence Pasquier,Niklas Mattsson,Christer Nilsson,Oskar Hansson,Julia Keith,Mario Masellis,Sandra E. Black,Jordi A. Matías-Guiu,María Nieves Cabrera-Martín,Claire Paquet,Julien Dumurgier,Marc Teichmann,Marie Sarazin,Marie Sarazin,Michel Bottlaender,Michel Bottlaender,Bruno Dubois,Christopher C. Rowe,Victor L. Villemagne,Rik Vandenberghe,Elias Granadillo,Edmond Teng,Mario F. Mendez,Philipp T. Meyer,Lars Frings,Alberto Lleó,Rafael Blesa,Juan Fortea,Sang Won Seo,Janine Diehl-Schmid,Timo Grimmer,Kristian Steen Frederiksen,Pascual Sánchez-Juan,Gaël Chételat,Willemijn J. Jansen,Rémi W. Bouchard,Robert Laforce,Pieter Jelle Visser,Rik Ossenkoppele,Rik Ossenkoppele +94 more
TL;DR: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants, PET/CSF biomarkers are used.
Journal ArticleDOI
TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations
Harro Seelaar,H. Jurgen Schelhaas,Asma Azmani,Benno Küsters,Sonia M. Rosso,Danielle Majoor-Krakauer,Maarten C. de Rijik,Patrizia Rizzu,Ming ten Brummelhuis,Pieter A. van Doorn,Wouter Kamphorst,Rob Willemsen,John C. van Swieten +12 more
TL;DR: There exists considerable clinical variation within families with FTD + MND, which may be determined by other genetic or environmental factors.
Journal ArticleDOI
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration
Alice Chen-Plotkin,Maria Martinez-Lage,Maria Martinez-Lage,Patrick M. A. Sleiman,William T. Hu,Robert W. Greene,Elisabeth M. Wood,Shaoxu Bing,Murray Grossman,Gerard D. Schellenberg,Kimmo J. Hatanpaa,Myron F. Weiner,Charles L. White,William S. Brooks,William S. Brooks,Glenda M. Halliday,Glenda M. Halliday,Jillian J. Kril,Marla Gearing,Thomas G. Beach,Neill R. Graff-Radford,Dennis W. Dickson,Rosa Rademakers,Bradley F. Boeve,Stuart Pickering-Brown,Julie S. Snowden,John C. van Swieten,Peter Heutink,Harro Seelaar,Jill R. Murrell,Bernardino Ghetti,Salvatore Spina,Salvatore Spina,Jordan Grafman,Jeffrey Kaye,Randall L. Woltjer,M.-Marsel Mesulam,Eileen H. Bigio,Albert Lladó,Bruce L. Miller,Ainhoa Alzualde,Fermin Moreno,Jonathan D. Rohrer,Ian R. A. Mackenzie,Howard Feldman,Howard Feldman,Ronald L. Hamilton,Marc Cruts,Marc Cruts,Sebastiaan Engelborghs,Peter Paul De Deyn,Christine Van Broeckhoven,Christine Van Broeckhoven,Thomas D. Bird,Nigel J. Cairns,A. Goate,Matthew P. Frosch,Peter Riederer,Nenad Bogdanovic,Virginia M.-Y. Lee,John Q. Trojanowski,Vivianna M. Van Deerlin +61 more
TL;DR: Patients with the c.26C>A mutation appeared to have a younger age at onset of FTLD and at death and more parkinsonian features than those with other GRN mutations, which differs in key features from GRN- FTLD-TDP.
Journal ArticleDOI
Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease
William T. Hu,William T. Hu,Harro Seelaar,Keith A. Josephs,David S. Knopman,Bradley F. Boeve,Eric J. Sorenson,Leo McCluskey,Lauren Elman,Helenius J. Schelhaas,Joseph E. Parisi,Benno Kuesters,Virginia M.-Y. Lee,John Q. Trojanowski,Ronald C. Petersen,John C. van Swieten,Murray Grossman +16 more
TL;DR: Distinct patterns of survival profiles exist in patients with frontotemporal dementia and motor neuron disease, and overall survival may depend on the relative timing of the emergence of secondary symptoms.